# AVITA Medical

AVITA Medical is an Asset Manager based in Valencia, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Valencia, United States
- **Region:** North America
- **Address:** Valencia, CA, United States
- **Assets under management:** Undisclosed
- **Website:** avitamedical.com

## Regulatory record

- **Reports private funds:** No

## About

AVITA Medical operates as a publicly traded commercial-stage regenerative medicine company. The firm secured FDA premarket approval for its RECELL Autologous Cell Harvesting Device, designed to prepare a spray-on suspension of a patient's own skin cells for the treatment of severe burns. Corbett has steered the organization since 2019, focusing commercialization on U.S. burn centers. The core technology centers on enzymatic disaggregation of a small split-thickness skin sample into a cellular suspension that can treat a wound up to 80 times the size of the donor site. The platform reduces donor-site morbidity and the number of surgical procedures for patients with large total body surface area burns. Key milestones include BARDA's multi-year partnership to expand RECELL's label for mass-casualty preparedness. The company maintains a direct sales force targeting Level 1 burn centers and has expanded into pediatric labelling and treatment of full-thickness burns. AVITA Medical is listed on both the Australian Securities Exchange and the Nasdaq. The company has pursued an adjacent launch into vitiligo treatment and soft-tissue reconstruction, diversifying beyond acute burn care. In recent periods, the organization has reported sequential quarter-over-quarter growth in commercial accounts, supported by increased procedural volumes at existing hospital customers. The firm's structural profile is that of a single-product platform scaling through regulatory pathway expansion. Unlike private-equity-backed competitors, AVITA operates with public-market capital and a narrow clinical focus, which creates a concentrated risk and reward profile tied directly to the adoption of RECELL across burn surgery protocols.

## Sectors

- Healthcare Services
- Digital Health

## People

- Jim Corbett — Chief Executive Officer

## Questions

### What is the clinical mechanism behind AVITA Medical's RECELL device?

RECELL uses a small sample of the patient's own healthy skin, disaggregates the cells with an enzyme-based process, and produces a spray-on cell suspension. This allows a donor site roughly 1/80th the size of the treatment area to cover large wounds, significantly reducing the need for conventional skin grafting and associated donor-site pain.

### Does AVITA Medical operate as a medical device company or a biologic therapeutics firm?

AVITA Medical is structured as a regenerative medicine company with a medical device platform. The RECELL device is an FDA-approved Class III medical device that processes autologous cells at the point of care without requiring an external laboratory or biologic manufacturing facility.

### What is the company's relationship with BARDA?

The Biomedical Advanced Research and Development Authority (BARDA) has a multi-year partnership with AVITA Medical to support the development and label expansion of RECELL for mass-casualty burn emergencies. This federal funding supports clinical studies that broaden the device's approved indications, including pediatric and full-thickness burn applications.

### How does AVITA Medical generate revenue?

Revenue comes primarily from sales of RECELL disposable cartridges and enzymes to U.S. burn centers, where the per-procedure cost is captured via hospital purchasing agreements. The company also records procedural milestone payments under its BARDA contract and is expanding into dermatology settings for vitiligo treatment.

### Which regulatory clearances has RECELL received?

RECELL holds FDA premarket approval for acute thermal burns in adults and pediatric patients, including full-thickness (third-degree) burns. The company received a subsequent approval for the RECELL GO platform in 2024 and has pursued FDA breakthrough device designation for vitiligo and soft-tissue reconstruction indications.

## Related profiles

- [Tri-County Financial Group](https://altss.com/profile/tri-county-financial-group-inc)
- [GENELUX Corp](https://altss.com/profile/genelux-corp)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/avita-medical-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology